R3767-ONC-1613: A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancies

February 11, 2017
https://clinicaltrials.gov/ct2/show/NCT03005782
Solid Tumors
Principal Investigator: Ding Wang, MD
Advanced Malignancies
Accepting Participants
(313)916-1784